# Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

> **NCT02249663** · PHASE3 · UNKNOWN · sponsor: **Teva Pharmaceuticals USA** · enrollment: 1535 (estimated)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Azelastine hydrochloride and Fluticasone propionate
- **DRUG:** Dymista™
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02249663
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2015-02
- **Final completion:** —
- **Target enrollment:** 1535 (ESTIMATED)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249663, "Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02249663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*